Primary Antiphospholipid Syndrome
The most likely underlying diagnosis is Primary Antiphospholipid Syndrome (answer b). This 27-year-old woman presents with the classic triad of antiphospholipid syndrome: recurrent pregnancy losses (three miscarriages), venous thromboembolism (prior DVT and now pulmonary embolism), and young age without other apparent risk factors.
Clinical Reasoning
The clinical presentation is pathognomonic for antiphospholipid syndrome:
- Recurrent miscarriages (three documented losses) - a hallmark obstetric manifestation
- Venous thromboembolism - both prior DVT and current large PE
- Young age (27 years) - thrombotic events in young patients without traditional risk factors strongly suggest underlying thrombophilia
- No features of other systemic diseases - absence of mentioned rash, joint symptoms, Raynaud's phenomenon, or other systemic manifestations
Why Not the Other Options?
SLE (option a): While antiphospholipid antibodies can occur in SLE (secondary antiphospholipid syndrome), this patient lacks any mentioned features of lupus such as rash, arthritis, serositis, or renal disease. The presentation is consistent with primary antiphospholipid syndrome 1.
Raynaud's disease (option c): No vascular spasm symptoms described; doesn't explain thrombosis or pregnancy losses.
Systemic scleroderma (option d): No skin thickening, digital ulcers, or pulmonary fibrosis mentioned.
Behçet's disease (option e): No oral/genital ulcers or uveitis described.
Critical Management Implications
The diagnosis has immediate therapeutic consequences per ESC guidelines:
Acute Management
- Avoid NOACs - The 2019 ESC guidelines explicitly state: "Do not use NOACs in patients with severe renal impairment or in those with antiphospholipid antibody syndrome" 1
- Use vitamin K antagonist (VKA/warfarin) with parenteral anticoagulation bridge until INR 2.0-3.0 achieved 1
Long-term Management
- Indefinite anticoagulation with VKA - "Continue oral anticoagulant treatment with a VKA indefinitely in patients with antiphospholipid antibody syndrome" 1
- This is recurrent VTE (DVT + PE) in the setting of a persistent thrombophilic condition
Common Pitfalls to Avoid
Do NOT prescribe NOACs (apixaban, rivaroxaban, dabigatran, edoxaban) - these have shown inferior efficacy and potentially increased thrombotic risk in antiphospholipid syndrome patients 1
Do NOT stop anticoagulation after 3-6 months - this is a lifelong condition requiring indefinite treatment
Confirm diagnosis with appropriate testing - lupus anticoagulant, anticardiolipin antibodies, and anti-β2-glycoprotein-I antibodies, repeated at 12 weeks to confirm persistence 2, 3, 4, 5
Supporting Evidence
Research confirms this clinical pattern: antiphospholipid syndrome presents with recurrent thrombosis (venous or arterial), pregnancy morbidity, and presence of antiphospholipid antibodies 2, 3, 4, 5. Studies document that 7-25% of recurrent spontaneous abortions are associated with antiphospholipid syndrome 4, and the combination of pregnancy loss with thrombotic events is highly specific for this diagnosis.
The guideline evidence is unequivocal about VKA preference over NOACs in this population, making accurate diagnosis critical for appropriate anticoagulant selection 1.